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Abstract
Doxorubicin (DOX) has not only chronic, but also acute toxic effects in the heart, ascribed to the generation of reactive oxygen species
(ROS). Focusing on the DOX-induced early biochemical changes in rat cardiomyocytes, we demonstrated that lipid peroxidation is an early
event, in fact conjugated diene production increased after 1-h DOX exposure, while cell damage, evaluated as lactate dehydrogenase (LDH)
release, was observed only later, when at least one third of the cell antioxidant defences were consumed. Cell pre-treatment with a-tocopherol
(TC) inhibited both conjugated diene production and LDH release. In cardiomyocytes, DOX treatment caused a maximal increase in glucose
uptake at 1 h, demonstrating that glucose transport may represent an early target for DOX. At longer times, as the cell damage become
significant, the glucose uptake stimulation diminished. Immunoblotting of glucose transporter isoform GLUT1 in membranes after 1-h DOX
exposure revealed an increase in GLUT1 amount similar to the increase in transport activity; both effects were inhibited by aTC. Early lipid
peroxidation evokes an adaptive response resulting in an increased glucose uptake, presumably to restore cellular energy. The regulation of
nutrient transport mechanisms in cardiomyocytes may be considered an early event in the development of the cardiotoxic effects of the
anthracycline.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Doxorubicin (DOX), commercially and clinically known
as adriamycin, is a highly effective antineoplastic drug
against solid tumors and hematological malignancies and
is widely used in both pediatric and adult patients [1].
However, its clinical use is often limited by undesirable
side effects, especially a severe, cumulative and dose-
dependent cardiotoxicity [2,3]. Besides chronic toxic
effects, DOX has also acute toxic effects on the heart. The
chronic, long-term effects, developed only after several
weeks or months of treatment, include the onset of cardio-
myopathy that often leads to congestive heart failure. The
acute, short-term effects are clinically characterized by atrial
and ventricular dysrhythmias, a perycarditis–myocarditis
syndrome and acute hypertensive reactions occurring
shortly after the administration of the drug [4].
Various mechanisms have been ascribed to the DOX
long-term induced cardiotoxicity, including reduction of
ventricular h-adrenergic receptor density [5], inhibition of
nucleic acid and protein synthesis [6] as well as protease
activities [7]. The mechanism of DOX-induced short-term
toxicity is not fully elucidated, although acute alterations in
platelet-activating factor, prostaglandins, histamine and
intracellular calcium have been implicated [8]. One of the
most accepted mechanisms for the anthracycline-induced
early damage is now regarded as being mediated by a
continuous generation of oxy radicals from DOX via a
redox cycling. DOX undergoes redox activation in the
presence of certain flavin enzymes and mitochondrial com-
plexes I–III [9–12]. Recently, DOX was shown to undergo
reductive activation at the reductase domain of the enzyme
endothelial nitric oxide synthase [13] and at the level of the
multienzymatic complex of fatty acid delta-6-desaturase
[14] at a very early stage.
Conceivably, these reactive oxygen species (ROS) could
then damage membranes and may profoundly affect mem-
brane-associated proteins, including enzymes, receptors and
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transporters. A group of important membrane proteins is the
specialized glucose transporters (for a review, see Ref. [15]).
The heart expresses both the transporter isoform GLUT4,
important for the normal function and properties of cardiac
myocytes [16], and the GLUT1, which is thought to be at
least in part responsible for the basal uptake of glucose [17].
The transporter isoform GLUT4, largely confined to an
intracellular storage site, becomes recruited to the cell sur-
face under the influence of several stimuli, such as insulin,
contraction, and hypoxia [18–20]; also GLUT1 is recruited
to the plasma membrane by several stimuli including
insulin, metformin, serotonin and cathecolamies [21–23].
In many cell systems, it has been demonstrated that GLUT1
activity can be acutely stimulated also by oxidative stress
[24,25]. The mechanism by which cells react to oxidate
stress has been extensively studied but not completely
understood. In M07, a human megakaryocytic cell line,
the effect of H2O2 on transport Vmax could be ascribed to a
transporter translocation to the plasma membranes [26]. A
stimulation of glucose transport by many stimuli through an
activation of GLUTs preexisting in the plasma membrane
has also been described [27]. Thus, we decided to verify
whether DOX treatment, due to the ability of the drug to
generate ROS, could be able to modulate glucose transport
into the cardiac cell and possibly to influence the intra-
cellular distribution of GLUT isoforms.
In this study, using primary cultures of neonatal rat
ventricular cells, we have investigated the DOX-induced
cascade of early biochemical changes in the heart, demon-
strating the relationship between DOX-induced lipid perox-
idation and acute alterations in glucose transport. The
central role of early lipid peroxidation in the acute regu-
lation of glucose transport into the cardiac cells was con-
firmed by means of a-tocopherol (aTC) pre-treatment.
2. Materials and methods
2.1. Materials
Doxorubicin hydrochloride, aTC, horse serum (HS),
fetal calf serum (FCS), Ham F10 culture medium, phloretin,
2-deoxy-D-glucose (DOG), phenylmethylsulfonyl fluoride
(PMSF), N-tosyl-L-lysine chloromethyl ketone (TLCK), N-
tosyl-L-phenylalanine chloromethyl ketone (TPCK), 2,2V-
azinobis (3-ethylbenzo-6-thiazoline-6-sulfonic acid)
(ABTS) and Trolox were from Sigma Chemical (St. Louis,
MO, USA). 2-Deoxy-D-[2,6-3H]-glucose was from Amer-
sham (UK); nitrocellulose paper (BA 83) was obtained from
Schleicher and Schuell (Keene, NH, USA). Rabbit poly-
clonal antisera against rat GLUT1 and GLUT4, antirabbit
IgG conjugated to horseradish peroxidase, and Western
Blotting Luminol Reagent were purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA). Sulfosuccini-
midyl 6-(biotinamido) hexanoate (NHS-LC-biotin), strepta-
vidin-agarose beads and Micro BCA protein assay reagent
were purchased from Pierce (Rockford, IL, USA). UV-grade
acetonitrile was from Prolabo (Paris, France). All the other
chemicals and solvents were of the highest analytical grade.
Doxorubicin hydrochloride was dissolved in PBS at 1 mM
concentration and stored at  20 jC in the dark. The thawed
solution was diluted with culture medium to the appropriate
concentration and used immediately. aTC was dissolved in
ethanol at 5mM concentration, stored at  20 jC, and diluted
with culture medium to the appropriate concentration.
2.2. Cell cultures
Primary heart cell cultures were obtained by isolation of
cardiomyocytes from the ventricles of 2–4 days old Wistar
rats, as previously reported [28]. Cells were grown in 60
mm Petri dishes until confluence in nutrient mixture Ham
F10 supplemented with 10% v/v FCS and 10% v/v HS. At
confluence, cardiomyocytes were supplemented with 20 AM
aTC. Twenty-four hours later, cultures were exposed to 1
AM DOX for different times. Appropriate control groups
were processed in the same way in the absence of aTC or
DOX.
2.3. Determination of conjugate dienes
The appearance of conjugate diene containing lipids was
evaluated as an index of lipid peroxidation using the method
of Burton et al. [29]. Cells were washed three times with
control medium supplemented with 10% FCA and 10% HS,
and two times with PBS. Preliminary experiments demon-
strated that DOX is completely removed by these washes.
All the cells were scraped off in ice-cold methanol, and
extracted in chloroform/methanol/water (2:1:1 v/v). The
chloroform layers from two extractions were combined
and then dried under nitrogen. Samples were resuspended
in a known volume of acetonitrile and the absorbance
determined at 235 nm.
2.4. Determination of the total antioxidant activity (TAA)
TAA, a marker of the cell antioxidant status, was
measured on the 800 g supernatant of cardiomyocytes
scraped off in ice-cold buffer and homogenated as reported
by Re et al. [30]. This method is based on the ability of the
antioxidant molecules in the cell extract to reduce the radical
cation of ABTS, determined by the decolorization of
ABTSj+ and measured as quenching of absorbance at 740
nm. Values obtained for each sample were compared to the
concentration–response curve of a standard Trolox solution,
and expressed as Trolox Equivalent Antioxidant Activity
(TEAC, Amol/ml).
2.5. Lactate dehydrogenase (LDH) release
LDH release was monitored before cell scraping by
collecting aliquots of medium from each dish; these aliquots
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were then analyzed spectrophotometrically for LDH activity
by measuring NADH levels at 340 nm [31].
2.6. Glucose transport assay
Glucose uptake was determined following Berridge
and Tan [32], with slight modifications. Confluent cells
on 60-mm culture plates were washed twice with ice-cold
PBS followed by the addition of 1 ml of PBS at 37 jC.
A mixture of 2-deoxy-D-[2,6-3H]glucose (0.4 ACi/assay)
and 1.0 mM unlabeled glucose analogue was added to
each dish, and incubation performed for 5 min at 37 jC
under conditions where the uptake was linear at least for
20 min. The uptake was stopped with phloretin (final
concentration 0.2 mM). The cells were washed with PBS
and scraped after the addition of 1 ml of lysis buffer (20
mM HEPES, 2 mM EDTA, 0.1% CHAPS and 0.1%
Triton). Sample radioactivity was measured by liquid
scintillation counting.
2.7. Biotinylation of plasma membranes
Biotinylation was performed as previously described
[33]. Confluent cells were rinsed with ice-cold PBS at
pH 8.0 followed by the addition of 1.5 ml of cold
biotinylation buffer (120 mM NaCl, 30 mM NaHCO3
and 5 mM KCl, pH 8.5) containing 0.1 mg/ml freshly
added NHS-LC-biotin. After 30 min of gentle swirling at
4 jC, the medium was aspirated and the plates were
washed with buffer containing 140 mM NaCl, 20 mM
Tris and 5 mM KCl, pH 7.5. Cells were then scraped and
pooled in 1 ml of hypotonic homogenization buffer
containing 10 mM NaHCO3 and a 100 AM concentration
each of TPCK, TLCK and PMSF. After 10 min on ice,
the cells were homogenized in a Potter homogenizer with
20 strokes, and 0.1 ml of buffer containing 1.5 M NaCl
and 100 mM Tris (pH 7.0) was added. The homogenates
were spun for 15 s at 18,000 g to sediment nuclei. The
resulting postnuclear supernatants were added to 1.5 ml
Eppendorf Microfuge tubes containing 50 Al of strepta-
vidin-agarose beads that had been sedimented following
pre-equilibration with 1 ml of homogenization buffer. An
additional 5 Al aliquot of 20 mM PMSF was added to
each mixture. After gentle mixing of the samples at 4 jC
for 30 min, the beads were pelleted and washed with 1
ml of homogenization buffer containing freshly added
protease inhibitors. The final pellets were resuspended in
Laemmli buffer and incubated at 65 jC for 30 min. The
beads were once again briefly pelleted and the super-
natants containing solubilized plasma membranes were
removed and frozen overnight prior to use.
2.8. SDS-PAGE and Western blot analysis
Cell fractions containing equal amounts of protein (20 Ag
of protein/lane) were added with bromophenol blue and
boiled for 3 min. Proteins were separated on 10% SDS-
polyacrylamide gel using a Mini-Protean II apparatus (Bio-
Rad Laboratories, CA, USA). Proteins were transferred
electrophoretically to supported nitrocellulose membrane
at 100 V for 60 min. Nonspecific binding was blocked by
incubating in TBS/Tween, pH 8.0 containing 5% nonfat
dried milk for 1 h at room temperature. Then, the nitro-
cellulose membranes were incubated overnight at 4 jC with
rabbit polyclonal antiserum against rat GLUT1 or GLUT4 at
1:1000 dilution. Blots were washed with TBS/Tween and
then incubated for 30 min at room temperature with anti-
rabbit IgG conjugated to horseradish peroxidase diluted
1:2000 in TBS/Tween containing 5% nonfat dried milk.
Membranes were washed with TBS/Tween and developed
using Western Blotting Luminol Reagent. Semiquantitative
analysis of specific immunolabeled bands was performed
using a Fluor S image analyzer (BioRad Laboratories).
2.9. Protein determination
Protein concentration was determined using the Bradford
method [34]. Before electrophoresis, because of the pres-
ence of high concentrations of SDS in some samples, the
protein content was determined by means of a micro-BCA
protein assay kit from Pierce, using bovine serum albumin
as a standard.
2.10. Statistical analysis
Data are meansF S.D. of at least four different cell
cultures. Statistical differences were evaluated using the
Student’s t-test.
3. Results
Peroxidation of unsaturated lipids leads to the formation
of conjugate diene-containing lipids. The exposure of car-
diomyocytes to DOX caused the formation of conjugate
diene-containing lipids in the very early phases of treatment.
In Fig. 1, conjugate diene production in control and aTC-
supplemented cells is reported in function of the time of
exposure to 1 AM DOX as 235 nm absorbance. aTC
treatment did not influence conjugate diene production in
cells not exposed to DOX independently of the time (data
not shown). DOX caused a significant increase (about 1.6-
fold) in conjugate diene levels at the first hour of treatment
in comparison to cells not exposed to the drug, and a linear
correlation between conjugate diene production and the time
of exposure was revealed in the first three hours (r = 0.996,
P < 0.01). A 6-h treatment did not evidence any significant
difference in comparison to a 3-h treatment. Conjugated
diene production in cells supplemented with aTC was
similar to cells not exposed to DOX at each time point
and significantly lower than in cells exposed to DOX and
not supplemented with the antioxidant.
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In order to correlate lipid peroxidation to intracellular
antioxidant status, TAA was evaluated in cardiomyocytes
exposed to 1 AM DOX for different times (Table 1). TAA
appeared always higher in cells not exposed than in cells
exposed to DOX, and the decrease in the TAA of unsup-
plemented cells was significantly correlated to the time of
exposure to the drug in the first three hours (r= 0.983,
P < 0.02), in agreement with the observed production of
conjugated dienes. A significant increase in TAA was
achieved by supplementing cells with aTC, and the value
remained always higher to that of unsupplemented cells at
each time point.
To investigate the integrity of plasma membranes, LDH
leakage from cultured cardiomyocytes, an indication of cell
injury, was examined. The release of LDH from unsupple-
mented and aTC supplemented cardiomyocytes exposed to
1 AM DOX for different times is reported in Fig. 2. aTC
pre-treatment did not influence LDH release in cells not
exposed to DOX independently of the time (data not
shown). An about 1.7-fold increase in LDH release was
demonstrated in cardiomyocytes exposed to the anthracy-
cline in the absence of aTC only after 3 h of DOX
exposition. A 6-h treatment did not evidence any significant
difference in comparison to the 3-h treatment. A protection
was achieved by the addition of aTC to cardiomyocytes,
LDH release value being similar to that observed in cells not
exposed to the drug and significantly lower than in cells
exposed to DOX and not supplemented with the antioxidant.
The time course of the effect of DOX treatment on DOG
transport in cultured cardiomyocytes is reported in Fig. 3.
DOG uptake is reported as the percentage of not exposed
cells (25787 cpm/mg protein/5 min = 100%). DOG uptake
did not evidence significant differences at any time point in
the absence of DOX treatment, indicating that the basal rate
of glucose transport remained constant. Upon DOX expo-
sure, DOG transport rose about 2-fold within 1 h, when
compared to the initial, not exposed control cells. The
treatment of cells for 2 h decreased the incremental increase
in glucose transport due to 1 AM DOX exposure by 15%,
although this value was not significantly different from that
observed at 1-h treatment. The incremental increase in DOG
transport was almost completely suppressed at 3- and 6-h
Table 1
Time course of the effect of 10 6 M DOX on cell TAA in cultured
cardiomyocytes in the absence or presence of DOX
DOX treatment (h) TEAC (Amol/ml)
Not supplemented 20 AM aTC
0 96.17F 3.19 159.86F 5.11
1 80.16F 3.18* 140.17F 4.18*
2 70.45F 4.53* 128.84F 5.36*
3 63.33F 4.13* 125.92F 4.25*
6 61.43F 3.89* 124.89F 5.12*
Total antioxidant activity was evaluated by measuring the ability of the cell
extract to reduce the radical cation of ABTS, as reported in Materials and
methods. Values obtained for each sample were compared to the
concentration–response curve of a standard Trolox solution, and expressed
as TEAC (Amol/ml). Data are meansF S.D. of four different determi-
nations. Statistical analysis was performed by the Student’s t-test comparing
cardiomyocytes exposed to DOX vs. the corresponding cardiomyocytes not
exposed to DOX: *P<0.001. In comparison to the corresponding
unsupplemented cells, statistical analysis revealed a significant increase in
TEAC at each time of DOX treatment: P < 0.001.
Fig. 2. Time course of the effect of 1 AM DOX on LDH release in the
culture medium of cardiomyocytes in the absence or presence of aTC. LDH
release was measured on aliquots of culture media as reported in Materials
and methods. Data are meansF S.D. of five different cell cultures.
Statistical analysis was performed by the Student’s t-test comparing
cardiomyocytes exposed to DOX vs. cardiomyocytes not exposed to DOX:
*P < 0.001. In comparison to the corresponding cells supplemented with 20
AM aTC, statistical analysis revealed a significant increase in LDH release
only at 3 and 6 h of DOX treatment: *P < 0.001.
Fig. 1. Time course of the effect of 1 AM DOX on conjugated diene-
containing lipids in cultured cardiomyocytes in the absence or presence of
aTC. Conjugated diene production was measured as 235 nm absorbance as
reported in Materials and methods. Data are meansF S.D. of five different
cell cultures. Statistical analysis was performed by the Student’s t-test
comparing cardiomyocytes exposed to DOX vs. cardiomyocytes not
exposed to DOX: *P < 0.001. In comparison to the corresponding cells
supplemented with 20 AM aTC, statistical analysis revealed a significant
increase in conjugated diene production at each time of DOX treatment:
*P < 0.001.
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DOX treatment. Pre-treatment of cardiomyocytes with aTC
for 24 h completely abolished the DOX-induced enhance-
ment in DOG uptake, but did not influence the basal glucose
transport.
In order to clarify the molecular basis for the early
stimulation of glucose transport by DOX, immunoblotting
analysis was performed in a plasma membrane-enriched
fraction of cardiomyocytes exposed to DOX for 1 h, a
condition at which we observed the maximal stimulation
of glucose uptake without causing LDH leakage. In order to
quantify the relative abundance of GLUTs at the surface of
cardiomyocytes previously exposed to DOX, in the absence
and in the presence of aTC, Western blot analysis of plasma
membrane-enriched fraction with anti-GLUT4 antibodies
was performed and GLUT4 relative abundance was quanti-
fied using scanning densitometry; no significant differences
in GLUT4 amount in membranes of cells exposed to the drug
was detected in comparison to cells not exposed (data not
shown). Similarly, Western blot analysis of plasma mem-
brane-enriched fraction with anti-GLUT1 antibodies was
performed, and GLUT1 relative abundance was quantified
using scanning densitometry. Fig. 4A shows a representative
immunoblot evidencing the effect of 1-h DOX treatment on
GLUT1 content in the plasma membrane-enriched fraction,
in the absence and presence of aTC. The intensity of GLUT1
immuno-reactive protein in the plasma membrane fraction of
DOX-treated cells was increased compared to not exposed
cells. Densitometric analysis indicate that GLUT1 content in
the plasma membranes of cells treated with DOX was
increased by about 2.0-fold as compared to GLUT1 from
untreated cells (Fig. 4B). aTC supplementation was able to
completely suppress the recruitment of the transporter to the
membrane fraction without influencing basal GLUT1 level.
Interestingly, the DOX-dependent increase in glucose trans-
port, following 1-h treatment, is of similar extent to the
increase in GLUT1 content in the plasma membrane-
enriched fraction.
4. Discussion
DOX-induced cardiotoxicity occurs in a biphasic manner,
an acute phase and a delayed phase, characterized by elec-
trophysiological abnormalities and congestive heart failure,
Fig. 4. Western blot and densitometric analysis of GLUT1 content in
plasma membrane-enriched fraction of cultured cardiomyocytes after 1 h
exposure to 1 AM DOX in the absence or presence of aTC. Plasma
membrane-enriched fraction was prepared from cultured cardiomyocytes
after 1 h exposure to 1 AMDOX as described in Materials and methods. (A)
Representative immunoblot showing the effect of 20 AM aTC on GLUT1
translocation in response to 1 h exposure to 1 AM DOX. Twenty
micrograms of protein per lane was separated by SDS-PAGE on 10%
polyacrylamide gels, transferred to nitrocellulose membrane and immu-
noassayed using anti-GLUT1 antibodies. Corresponding bands migrating
at c 55 kDa are shown. (B) Results of scanning densitometry analysis
performed on four independent autoradiographs for GLUT1 are presented.
Relative amounts (meansF S.D.) are in arbitrary units and compared to the
corresponding GLUTs from cells not exposed to the drug; *P< 0.001 vs.
controls.
Fig. 3. Time course of the effect of 1 AM DOX on DOG uptake in cultured
cardiomyocytes in the absence or presence of aTC. Confluent cardiomyo-
cytes were exposed to 1 AM DOX for the indicated periods of time in the
absence or the presence of 20 AM aTC. At the end of the incubation
periods, the plates were rinsed and DOG transport was measured for 5 min
as described in Materials and methods. Data are reported as percent of
control cells (no DOX and no aTC; 25787 cpm/mg protein/5 min = 100%).
Data are meansF S.D. of four different cell cultures. Statistical analysis
was performed by the Student’s t-test comparing cardiomyocytes exposed
to DOX vs. cardiomyocytes not exposed to DOX: *P < 0.001. In com-
parison to the corresponding cells supplemented with 20 Am aTC,
statistical analysis revealed a significant increase in glucose uptake only at 1
and 2 h of DOX treatment: *P < 0.001.
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respectively [35]. One hypothesis for the mechanism for the
acute phase is the involvement of free radicals [9–14] that
could then damage membrane phospholipids leading to lipid
peroxidation. The cultured cardiomyocyte model has
enabled us to demonstrate that lipid peroxidation is an early
event. Similar results were obtained by Luo et al. [36] who
demonstrated that aldehydic lipid peroxidation products in
rat heart tissue increased significantly after 1-h drug treat-
ment. DOX-induced lipid peroxidation could potentially
account for a parallel increase in LDH release. LDH leakage
was significantly increased only after 3-h treatment, indicat-
ing that lipid peroxidation is a very early event that induces
cell damage only at longer times. In rats treated with a bolus
injection of DOX, creatine kinase activity in rat plasma, a
clinical marker for the determination of cardiac damage, was
significantly elevated only 2–4 h after treatment [36] and in
rats receiving DOX for two or three doses every third day,
a significant creatine kinase release was detected only at day
7 [37].
Differences in the antioxidant capacity of tissues can
explain why cardiac tissue develops early lipid peroxidation
after DOX administration, whereas other tissues, such as the
liver, are relatively resistant to damage. It has been reported
that the activity of antioxidant enzymes is lower and the
susceptibility to oxidative stress is higher in rat heart than in
other tissues such as the liver [38,39]. In fact, TAA was
greatly affected by DOX treatment and it decreased almost
linearly as the time of exposure to the drug increased, but
cell damage was evidenced only when at least one-third of
the cell antioxidant defences were consumed and free
radicals exceed the capacity of the cellular intrinsic free
radical scavenging system, becoming cytotoxic.
The relationship between DOX-induced lipid peroxida-
tion and LDH release was demonstrated by cell pre-treatment
with aTC, in which both phenomena were significantly
inhibited by the antioxidant. Vitamin E supplementation
significantly increased the TAA in comparison to unsupple-
mented cells, and the TAAvalue remained always higher than
that observed in not treated, not supplemented cells. The 20
AM aTC dose used in this study has been reported to increase
cellular aTC content and to reduce membrane lipid alteration,
to enhance the recovery of contractile function and to reduce
the accumulation of calcium in isolated rat hearts exposed to
global ischemia and reperfusion [40]. Recently, we demon-
strated that such a aTC dose was able to inhibit both lipid
peroxidation and alterations in fatty acid composition in-
duced by a longer (24 h) DOX treatment in cultured cardi-
omyocytes [41]. Moreover, while cardiomyocytes not
exposed to DOX contracted spontaneously in culture with
steady, deep, rhythmic contractions at rates of 150F 32 beats
per minute, chronic exposure to DOX for 24 h caused an
asynchrony in the contractile activity of exposed cultures
leading to a slowing of beating rate to 86F 27 beats per
minute. Cardiomyocytes pretreated with aTC exhibited a
maintenance of contractile function with a beating rate of
146F 29 beats per minute (S. Hrelia et al., unpublished data).
DOX has been reported to cause inhibition of h-oxidation
of long-chain fatty acids [42] with consequent depletion of
cardiac ATP and switch to anaerobic glycolysis [43]. Since in
the heart glucose transport limits the glycolytic rate, its
regulation may be important in maintaining the cell energy
status. The present study provides a first direct demonstra-
tion that the glucose transport system in the cardiomyocytes
may represent one of the early targets of the anthracycline.
DOX caused the maximal increase in DOG uptake at 1-h
treatment, when no detectable cell damage was evidenced.
Only at longer times of drug exposure the incremental
increase in DOG uptake diminished, as the progressive,
irreversible cell damage became significant. The relationship
between the increase in glucose transport and the increase in
lipid peroxidation was evidenced by the ability of vitamin E
to counteract this effect.
Glucose transport may be determined by the number of
glucose transporters in the plasma membrane, and/or by the
intrinsic activity of these transporters. Cardiac myocytes
express both GLUT4 and GLUT1, and although GLUT4 is
quantitatively the most important glucose transporter
expressed in these cells, GLUT1 is also expressed at a
substantial level. GLUT4 levels in membrane-enriched frac-
tions did not change following DOX treatment; similar
results were obtained by Rudich et al. [44] who demonstrated
the impaired insulin-stimulated GLUT4 translocation fol-
lowing oxidative stress in 3T3-L1 adipocytes. Western blot
and densitometric analysis of GLUT1 in cardiomyocyte
membrane-enriched fractions after 1-h exposure to 1 AM
DOX revealed that GLUT1 amount had approximately a 2-
fold increase. Although the accuracy of the transport assay
was higher in comparison to the densitometric analysis, the
increase in GLUT1 transporter isoform content correlates
well to the degree of enhancement in glucose transport and,
similarly, aTC pre-treatment was able to inhibit the enhance-
ment both in glucose transport and in GLUT1 content. Since
glucose transport is largely determined by the number of
glucose transporters present in the plasma membrane of
cardiomyocytes, the effect of DOX on early regulation of
glucose transport is likely to be based on the observed
changes in GLUT1 distribution. Enhanced glucose uptake
in cardiac cells can be achieved by rapid translocation of
preexisting transporters from intracellular pools to the
plasma membrane. In the case of short-term DOX exposure,
glucose transport stimulation is an early phase response
involving redistribution of preexisting GLUT1 transporters
and different to that observed following anoxia, glucose
deprivation or treatment with iron chelators, which occurs
only later and involves GLUT1 gene induction [45,46]. The
role of ROS produced by DOX in mediating GLUT1 recruit-
ment to the plasma membrane is demonstrated by the effect
that aTC had in preventing glucose uptake stimulation and
transporter translocation. Interestingly, the effect of DOX-
induced early lipid peroxidation on glucose transporter
redistribution and expression in plasma membrane seems
to be a unique property of the heart. In fact, it has recently
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been demonstrated that DOX treatment did not change the
amount and the appearance of GLUT1 transporter in cancer
cells, as Erlich ascites carcinoma cells [47].
5. Conclusions
The present work focuses on the events that occur prior
to irreversible cell damage caused by DOX to cardiomyo-
cytes and demonstrates that DOX-induced lipid peroxida-
tion is the main culprit of the short-term damage that set the
stage of an adaptive response which resulted in a increased
glucose uptake, presumably to restore cellular energy.
Although the molecular mechanism by which DOX triggers
redistribution of GLUT1 and thus regulates glucose uptake
in heart cells remains to be elucidated, data here reported
suggest that regulation of nutrient transport mechanisms in
cardiomyocytes may be considered a peroxidation-depend-
ent early event in the development of the cardiotoxic effects
of the anthracycline, and set the stage of future interventions
in counteracting the side effects of the clinical use of DOX.
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